BEI's Research Record domain provides public-record transparency analysis. It does not provide medical advice, diagnosis, treatment recommendations, legal conclusions, investment advice, or claims of clinical efficacy. All outputs are evidence-record summaries based on cited public sources.
Research Record
Clinical Trial Registry Transparency
BEI maps the public evidence record of clinical research sponsors — sourced exclusively from the ClinicalTrials.gov federal registry. We report what the public record shows. We do not interpret medicine.
How this works
Each profile is built from a ClinicalTrials.gov v2 API query, structured into BEI's four-layer evidence envelope (Observation / Context / Signal / Unknowns), and screened by the CASEY publish gate before appearing here. Profiles failing the gate are withheld pending review. All outputs cite their primary source; we do not host trial documents.
National Center for Research Resources (NCRR)
NIH
Limited
70
Registered trials
80%
COMPLETED status
0%
Results posted
3
TERMINATED
Observation
70 trials registered under "National Center for Research Resources (NCRR)" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 56 COMPLETED, 0 recruiting or active, 3 TERMINATED, 0 WITHDRAWN, 11 other.
Of 56 completed trials: 0 posted results; 56 did not post results as of the fetch date.
Conditions listed: 5'-Nucleotidase Syndrome, Acquired Immunodeficiency Syndrome, Addison's Disease, Alpha 1-Antitrypsin Deficiency, Amyloidosis and 91 more.
Signal · limited
The registry shows completed trials without posted results — 0% of completed trials (0 of 56) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
National Cancer Institute (NCI)
NIH
High confidence
29
Registered trials
62%
COMPLETED status
39%
Results posted
3
TERMINATED
Observation
29 trials registered under "National Cancer Institute (NCI)" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 18 COMPLETED, 7 recruiting or active, 3 TERMINATED, 0 WITHDRAWN, 1 other.
Of 18 completed trials: 7 posted results; 11 did not post results as of the fetch date.
Conditions listed: ALL, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Adrenal Cortical Carcinoma, Adrenocortical Carcinoma and 253 more.
Signal · high
The registry shows completed trials without posted results — 39% of completed trials (7 of 18) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
AstraZeneca
INDUSTRY
High confidence
25
Registered trials
80%
COMPLETED status
35%
Results posted
1
TERMINATED
Observation
25 trials registered under "AstraZeneca" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 20 COMPLETED, 3 recruiting or active, 1 TERMINATED, 0 WITHDRAWN, 1 other.
Of 20 completed trials: 7 posted results; 13 did not post results as of the fetch date.
Conditions listed: Acute Coronary Syndrome, Alzheimer's Disease, Breast Cancer, Cardiovascular Death, Chronic Kidney Disease and 24 more.
Signal · high
The registry shows completed trials without posted results — 35% of completed trials (7 of 20) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Assistance Publique - Hôpitaux de Paris
OTHER
High confidence
25
Registered trials
32%
COMPLETED status
0%
Results posted
5
TERMINATED
Observation
25 trials registered under "Assistance Publique - Hôpitaux de Paris" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 8 COMPLETED, 7 recruiting or active, 5 TERMINATED, 1 WITHDRAWN, 4 other.
Of 8 completed trials: 0 posted results; 8 did not post results as of the fetch date.
Conditions listed: ANCA Associated Systemic Vasculitis Including Wegener's, Adenocarcinoma, Pancreas, Alzheimer Disease, Antiphospholipid Syndrome, Atherosclerotic Stenosis and 48 more.
Signal · high
The registry shows completed trials without posted results — 0% of completed trials (0 of 8) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
M.D. Anderson Cancer Center
OTHER
High confidence
22
Registered trials
45%
COMPLETED status
50%
Results posted
6
TERMINATED
Observation
22 trials registered under "M.D. Anderson Cancer Center" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 10 COMPLETED, 3 recruiting or active, 6 TERMINATED, 1 WITHDRAWN, 2 other.
Of 10 completed trials: 5 posted results; 5 did not post results as of the fetch date.
Conditions listed: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Bile Duct Carcinoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Breast Cancer and 103 more.
Signal · high
The registry shows 50% of completed trials (5 of 10) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Washington University School of Medicine
OTHER
High confidence
19
Registered trials
37%
COMPLETED status
43%
Results posted
5
TERMINATED
Observation
19 trials registered under "Washington University School of Medicine" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 7 COMPLETED, 4 recruiting or active, 5 TERMINATED, 3 WITHDRAWN, 0 other.
Of 7 completed trials: 3 posted results; 4 did not post results as of the fetch date.
Conditions listed: Alzheimer Disease, Alzheimers Disease, Alzheimers Disease, Familial, Ataxia, Carcinoma, Hepatocellular and 43 more.
Signal · high
The registry shows completed trials without posted results — 43% of completed trials (3 of 7) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
GlaxoSmithKline
INDUSTRY
High confidence
18
Registered trials
83%
COMPLETED status
33%
Results posted
2
TERMINATED
Observation
18 trials registered under "GlaxoSmithKline" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 15 COMPLETED, 1 recruiting or active, 2 TERMINATED, 0 WITHDRAWN, 0 other.
Of 15 completed trials: 5 posted results; 10 did not post results as of the fetch date.
Conditions listed: Alzheimer's Disease, Atherosclerosis, Cancer, Cardiovascular Disease, Diabetes Mellitus, Type 2 and 3 more.
Signal · high
The registry shows completed trials without posted results — 33% of completed trials (5 of 15) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Pfizer
INDUSTRY
High confidence
17
Registered trials
65%
COMPLETED status
64%
Results posted
4
TERMINATED
Observation
17 trials registered under "Pfizer" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 11 COMPLETED, 2 recruiting or active, 4 TERMINATED, 0 WITHDRAWN, 0 other.
Of 11 completed trials: 7 posted results; 4 did not post results as of the fetch date.
Conditions listed: Alzheimer Disease, Alzheimer's Disease, Breast Cancer, Carcinoma, Renal Cell, Colorectal Adenocarcinomas and 12 more.
Signal · high
The registry shows 64% of completed trials (7 of 11) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Novartis Pharmaceuticals
INDUSTRY
High confidence
17
Registered trials
71%
COMPLETED status
67%
Results posted
3
TERMINATED
Observation
17 trials registered under "Novartis Pharmaceuticals" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 12 COMPLETED, 1 recruiting or active, 3 TERMINATED, 1 WITHDRAWN, 0 other.
Of 12 completed trials: 8 posted results; 4 did not post results as of the fetch date.
Conditions listed: Alzheimer's Dementia, Alzheimer's Disease, Alzheimers Disease, Cancer, Central Retinal Vein Occlusion and 19 more.
Signal · high
The registry shows 67% of completed trials (8 of 12) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Novo Nordisk A/S
INDUSTRY
High confidence
17
Registered trials
88%
COMPLETED status
27%
Results posted
1
TERMINATED
Observation
17 trials registered under "Novo Nordisk A/S" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 15 COMPLETED, 1 recruiting or active, 1 TERMINATED, 0 WITHDRAWN, 0 other.
Of 15 completed trials: 4 posted results; 11 did not post results as of the fetch date.
Conditions listed: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy.
Signal · high
The registry shows completed trials without posted results — 27% of completed trials (4 of 15) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Eli Lilly and Company
INDUSTRY
High confidence
16
Registered trials
81%
COMPLETED status
69%
Results posted
0
TERMINATED
Observation
16 trials registered under "Eli Lilly and Company" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 13 COMPLETED, 3 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 0 other.
Of 13 completed trials: 9 posted results; 4 did not post results as of the fetch date.
Conditions listed: Adolescent, Alzheimer Disease, Alzheimer's Disease, B-Cell Lymphoma, Brain Diseases and 20 more.
Signal · high
The registry shows 69% of completed trials (9 of 13) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Mayo Clinic
OTHER
High confidence
15
Registered trials
60%
COMPLETED status
11%
Results posted
0
TERMINATED
Observation
15 trials registered under "Mayo Clinic" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 9 COMPLETED, 6 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 0 other.
Of 9 completed trials: 1 posted results; 8 did not post results as of the fetch date.
Conditions listed: Abnormalities, Digestive System, Adenine Phosphoribosyltransferase Deficiency, Alzheimer Disease, Cancer of Esophagus, Cancer of the Esophagus and 53 more.
Signal · high
The registry shows completed trials without posted results — 11% of completed trials (1 of 9) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
NYU Langone Health
OTHER
High confidence
15
Registered trials
53%
COMPLETED status
0%
Results posted
2
TERMINATED
Observation
15 trials registered under "NYU Langone Health" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 8 COMPLETED, 3 recruiting or active, 2 TERMINATED, 2 WITHDRAWN, 0 other.
Of 8 completed trials: 0 posted results; 8 did not post results as of the fetch date.
Conditions listed: Adenine Phosphoribosyl Transferase Deficiency, Airway Disease, Alzheimer Disease, Alzheimer's Disease, Barrett Esophagus and 22 more.
Signal · high
The registry shows completed trials without posted results — 0% of completed trials (0 of 8) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
High confidence
14
Registered trials
71%
COMPLETED status
0%
Results posted
0
TERMINATED
Observation
14 trials registered under "National Heart, Lung, and Blood Institute (NHLBI)" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 10 COMPLETED, 3 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 1 other.
Of 10 completed trials: 0 posted results; 10 did not post results as of the fetch date.
Conditions listed: Aortic Aneurysm, Abdominal, Arrhythmia, Asthma, Atherosclerosis, Atrial Fibrillation and 30 more.
Signal · high
The registry shows completed trials without posted results — 0% of completed trials (0 of 10) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Memorial Sloan Kettering Cancer Center
OTHER
High confidence
14
Registered trials
71%
COMPLETED status
30%
Results posted
0
TERMINATED
Observation
14 trials registered under "Memorial Sloan Kettering Cancer Center" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 10 COMPLETED, 4 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 0 other.
Of 10 completed trials: 3 posted results; 7 did not post results as of the fetch date.
Conditions listed: All Cancers, Breast Cancer Survivors, Cancer, Cancer Survivor, Esophageal Cancer and 10 more.
Signal · high
The registry shows completed trials without posted results — 30% of completed trials (3 of 10) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Sanofi
INDUSTRY
High confidence
14
Registered trials
93%
COMPLETED status
54%
Results posted
1
TERMINATED
Observation
14 trials registered under "Sanofi" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 13 COMPLETED, 0 recruiting or active, 1 TERMINATED, 0 WITHDRAWN, 0 other.
Of 13 completed trials: 7 posted results; 6 did not post results as of the fetch date.
Conditions listed: Breast Cancer, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Type 2, Heart Defects, Congenital, Hypercholesterolemia and 5 more.
Signal · high
The registry shows 54% of completed trials (7 of 13) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Icahn School of Medicine at Mount Sinai
OTHER
High confidence
13
Registered trials
100%
COMPLETED status
8%
Results posted
0
TERMINATED
Observation
13 trials registered under "Icahn School of Medicine at Mount Sinai" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 13 COMPLETED, 0 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 0 other.
Of 13 completed trials: 1 posted results; 12 did not post results as of the fetch date.
Conditions listed: Alzheimer Disease, Alzheimer's Disease, Alzheimer's Disease and Related Dementias, Autism, Common Variable Immunodeficiency and 11 more.
Signal · high
The registry shows completed trials without posted results — 8% of completed trials (1 of 13) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
University of California, San Francisco
OTHER
High confidence
13
Registered trials
77%
COMPLETED status
20%
Results posted
1
TERMINATED
Observation
13 trials registered under "University of California, San Francisco" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 10 COMPLETED, 2 recruiting or active, 1 TERMINATED, 0 WITHDRAWN, 0 other.
Of 10 completed trials: 2 posted results; 8 did not post results as of the fetch date.
Conditions listed: Age Related Macular Degeneration, Alzheimer Disease, Amyotrophic Lateral Sclerosis (ALS), Behavioral Variant Frontotemporal Dementia (bvFTD), Bladder Cancer and 43 more.
Signal · high
The registry shows completed trials without posted results — 20% of completed trials (2 of 10) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
High confidence
12
Registered trials
75%
COMPLETED status
22%
Results posted
1
TERMINATED
Observation
12 trials registered under "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 9 COMPLETED, 1 recruiting or active, 1 TERMINATED, 1 WITHDRAWN, 0 other.
Of 9 completed trials: 2 posted results; 7 did not post results as of the fetch date.
Conditions listed: Abnormal Glucose Tolerance, Acute Liver Failure, Cystic Fibrosis, Diabetes, Diabetes Mellitus and 14 more.
Signal · high
The registry shows completed trials without posted results — 22% of completed trials (2 of 9) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
University of Southern California
OTHER
High confidence
12
Registered trials
58%
COMPLETED status
43%
Results posted
3
TERMINATED
Observation
12 trials registered under "University of Southern California" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 7 COMPLETED, 2 recruiting or active, 3 TERMINATED, 0 WITHDRAWN, 0 other.
Of 7 completed trials: 3 posted results; 4 did not post results as of the fetch date.
Conditions listed: Acute Myelogenous Leukemia, Age-related Cognitive Decline, Aging, Alzheimer Disease, Alzheimer's Disease (AD) and 20 more.
Signal · high
The registry shows completed trials without posted results — 43% of completed trials (3 of 7) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
University of British Columbia
OTHER
High confidence
12
Registered trials
50%
COMPLETED status
17%
Results posted
2
TERMINATED
Observation
12 trials registered under "University of British Columbia" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 6 COMPLETED, 2 recruiting or active, 2 TERMINATED, 1 WITHDRAWN, 1 other.
Of 6 completed trials: 1 posted results; 5 did not post results as of the fetch date.
Conditions listed: Alzheimer's Disease, Breast Cancer, Chronic Kidney Disease, Depressive Disorder, Diabetes and 15 more.
Signal · high
The registry shows completed trials without posted results — 17% of completed trials (1 of 6) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Hoffmann-La Roche
INDUSTRY
High confidence
12
Registered trials
67%
COMPLETED status
63%
Results posted
0
TERMINATED
Observation
12 trials registered under "Hoffmann-La Roche" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 8 COMPLETED, 4 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 0 other.
Of 8 completed trials: 5 posted results; 3 did not post results as of the fetch date.
Conditions listed: Alzheimer's Disease, Alzheimers Disease, Breast Cancer, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 and 8 more.
Signal · high
The registry shows 63% of completed trials (5 of 8) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Seoul National University Hospital
OTHER
High confidence
12
Registered trials
42%
COMPLETED status
0%
Results posted
1
TERMINATED
Observation
12 trials registered under "Seoul National University Hospital" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 5 COMPLETED, 1 recruiting or active, 1 TERMINATED, 0 WITHDRAWN, 5 other.
Of 5 completed trials: 0 posted results; 5 did not post results as of the fetch date.
Conditions listed: Acromegaly, Acute Coronary Syndrome, Alzheimer Disease, Alzheimer's Disease, Central Diabetes Insipidus and 18 more.
Signal · high
The registry shows completed trials without posted results — 0% of completed trials (0 of 5) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Assiut University
OTHER
High confidence
11
Registered trials
18%
COMPLETED status
0%
Results posted
0
TERMINATED
Observation
11 trials registered under "Assiut University" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 2 COMPLETED, 5 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 4 other.
Of 2 completed trials: 0 posted results; 2 did not post results as of the fetch date.
Conditions listed: Acute Ischemic Stroke, Anxiety Depression, Breast Cancer, Burnout, Cellular Diagnosis, Chronic Lymphocytic Leukemia and 10 more.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Merck Sharp & Dohme LLC
INDUSTRY
High confidence
11
Registered trials
73%
COMPLETED status
88%
Results posted
1
TERMINATED
Observation
11 trials registered under "Merck Sharp & Dohme LLC" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 8 COMPLETED, 1 recruiting or active, 1 TERMINATED, 1 WITHDRAWN, 0 other.
Of 8 completed trials: 7 posted results; 1 did not post results as of the fetch date.
Conditions listed: Alzheimer Disease, Alzheimer's Disease, Colorectal Cancer, Diabetes Mellitus, Non-Insulin-Dependent, Lymphoma and 5 more.
Signal · high
The registry shows 88% of completed trials (7 of 8) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
National Institute on Aging (NIA)
NIH
High confidence
11
Registered trials
73%
COMPLETED status
0%
Results posted
1
TERMINATED
Observation
11 trials registered under "National Institute on Aging (NIA)" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 8 COMPLETED, 0 recruiting or active, 1 TERMINATED, 0 WITHDRAWN, 2 other.
Of 8 completed trials: 0 posted results; 8 did not post results as of the fetch date.
Conditions listed: Aging, Alzheimer Disease, Alzheimer's Disease, Cognitive Decline, Dementia and 5 more.
Signal · high
The registry shows completed trials without posted results — 0% of completed trials (0 of 8) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Boehringer Ingelheim
INDUSTRY
High confidence
11
Registered trials
73%
COMPLETED status
50%
Results posted
1
TERMINATED
Observation
11 trials registered under "Boehringer Ingelheim" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 8 COMPLETED, 2 recruiting or active, 1 TERMINATED, 0 WITHDRAWN, 0 other.
Of 8 completed trials: 4 posted results; 4 did not post results as of the fetch date.
Conditions listed: Alzheimer Disease, Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Diabetes Mellitus, Type 2, Diabetic Nephropathies and 5 more.
Signal · high
The registry shows 50% of completed trials (4 of 8) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
National Taiwan University Hospital
OTHER
High confidence
11
Registered trials
9%
COMPLETED status
0%
Results posted
0
TERMINATED
Observation
11 trials registered under "National Taiwan University Hospital" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 1 COMPLETED, 2 recruiting or active, 0 TERMINATED, 0 WITHDRAWN, 8 other.
Of 1 completed trial: 0 posted results; 1 did not post results as of the fetch date.
Conditions listed: 18F-FDG PET, Advanced Cancer, Alzheimer Disease, Alzheimer's Disease, Antiphospholipid Syndrome and 25 more.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Massachusetts General Hospital
OTHER
High confidence
11
Registered trials
36%
COMPLETED status
75%
Results posted
0
TERMINATED
Observation
11 trials registered under "Massachusetts General Hospital" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 4 COMPLETED, 6 recruiting or active, 0 TERMINATED, 1 WITHDRAWN, 0 other.
Of 4 completed trials: 3 posted results; 1 did not post results as of the fetch date.
Conditions listed: Alzheimer Disease, Breast Cancer, Cancer, Dementia Prevention, Healthy Lifestyle Behaviors and 14 more.
Signal · high
The registry shows 75% of completed trials (3 of 4) had posted results as of the fetch date. The pattern is consistent with standard FDAAA reporting timelines.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
Data as of 2026-06-22 · Source: ClinicalTrials.gov (federal registry)
Janssen Research & Development, LLC
INDUSTRY
High confidence
10
Registered trials
50%
COMPLETED status
0%
Results posted
2
TERMINATED
Observation
10 trials registered under "Janssen Research & Development, LLC" in ClinicalTrials.gov as of 2026-06-22.
Status breakdown: 5 COMPLETED, 3 recruiting or active, 2 TERMINATED, 0 WITHDRAWN, 0 other.
Of 5 completed trials: 0 posted results; 5 did not post results as of the fetch date.
Conditions listed: Advanced or Metastatic Colorectal Cancer, Alzheimer Disease, Alzheimer's Disease, Healthy, Leukemia, Lymphocytic, Chronic, B-Cell and 3 more.
Signal · high
The registry shows completed trials without posted results — 0% of completed trials (0 of 5) had posted results as of the fetch date. This may indicate reporting delays, FDAAA exemptions, or data entry lag.
Alt. explanation: Reporting delay: results may be in preparation and not yet submitted.
Alt. explanation: FDAAA exemption: not all trials are subject to mandatory results reporting.
Alt. explanation: Data entry lag: the registry may not reflect results already published or submitted.
What we cannot determine (4)
Cannot determine from the registry alone whether unreported results are due to a regulatory exemption, an active reporting timeline, sponsor data-entry delay, or a decision not to report.
Cannot determine the completeness of this sponsor's trial portfolio: not all research requires ClinicalTrials.gov registration, and sponsor names may appear under multiple legal entity variations.
Cannot determine the clinical significance of any registry gap without reviewing the full study protocols, regulatory correspondence, and publication records.
Cannot determine whether conditions or intervention names in the registry fully reflect the breadth of the sponsor's research activity.
Could we be wrong? Registry data may lag actual trial activity by weeks to months. A trial without posted results may have results pending under a mandatory reporting window that has not yet elapsed, may qualify for a regulatory exemption, or may have been reported under a different sponsor name or a related entity. This profile reflects only what the ClinicalTrials.gov public registry showed at the fetch date.
